Dr Abby Douglas is an infectious diseases physician with an interest in antibiotic allergy and infections in the immunocompromised. She is the Peter MacCallum Cancer Centre medical lead of the Better Care Victoria-funded Antibiotic Allergy Discovery and Delabelling program, and a principal investigator of the Australian Severe Cutaneous Adverse Reaction to antibiotics research group. She has collaborated and published on projects relating to skin testing and oral challenge for antibiotic allergy. She is very pleased to present to this audience today.
Antimicrobial Allergy - Can We Turn The Tide On This Common Clinical Conundrum?
Antimicrobial allergy labels (AALs) are very common amongst Australian patients and affect prescribing and outcomes for patients Australia-wide, with higher rates of restricted antibiotic use, drug costs, medication error, antimicrobial-resistant infections, surgical site infections and longer length of stay. There is increasing evidence to show that not all allergies are forever, and that a significant proportion of patients can be “delabelled” by a process of detailed allergy phenotype evaluation, skin prick or patch testing, oral challenge and other potential investigational methods. AAL delabelling leads to a dramatic increase in appropriate antimicrobial prescribing and narrow spectrum antimicrobial use. An update on research surrounding antimicrobial allergy epidemiology and phenotypes, antimicrobial cross reactivity, the AAL diagnostic work up and outcomes of successful programs instituted in Melbourne, Australia will be presented.